Psychoemotional and cognitive characteristics in patients at the early stages of Parkinson’s disease


  • A. V. Demchenko Zaporizhzhia State Medical University, Ukraine,
  • V. V. Biriuk Zaporizhzhia State Medical University, Ukraine,



Parkinson disease, early stages, psychoemotional, cognitive function, cognitive evoked potentials Р300



The purpose of the study was to assess psychoemotional and cognitive characteristics in patients at the early stages of Parkinson’s disease (PD) by neuropsychological and neurophysiological examinations.

Materials and methods. A total of 40 PD patients with Hoehn and Yahr stage I–II (19 patients with stage I PD and 21 patients with stage II PD) were examined. A general physical examination and examination of the nervous system were performed in each group of patients. Neuropsychological characteristics were studied with the Unified Parkinson’s Disease Rating Scale (MDS UPDRS), the Beck Depression Inventory, Starkstein Apathy Scale, Zung Anxiety Rating Scale, Vein Night Sleep Scale, Boston Stress Test. The cognitive functions were examined by the Montreal Cognitive Assessment (MoCA) scale and cognitive evoked potentials (CEP) P300.

Results. A significant increase in PD symptoms (motor and non-motor) severity (P ˂ 0.001) according to MDS UPDRS data depending on PD stage was found. The anxiety level (P = 0.02) according to Zung Anxiety Rating Scale data and apathy level (P = 0.026) measured by Starkstein Apathy Scale, were significantly higher at stage II PD. Cognitive impairments were worsened according to the MoCA scale (P = 0.003) in 87.5 % of the patients. The prolongation of N2 latency in the right frontal area (P = 0.05) and P300 latency in all brain areas (P ˂ 0.01) were observed in stage II PD patients.

Conclusions. There was a significant difference between PD symptoms severity (motor and non-motor) in stage I and II PD patients according to MDS UPDRS. Stage II PD patients were characterized by worse cognitive impairments, increased level of anxiety and apathy as compared to stage I PD patients. The difference between cognitive decline severity in patients with PD depending on the stage was confirmed by P300 latency prolongation in stage II PD patients.


Grebysheva, T. S., Brazovskaya, N. G., Zhukova, I. A., Nikitina, M. A., Izhboldina, O. P., Zhukova, N. G., Alifirova, V. M., & Pekker, Ya. S. (2014). Primenenie bioupravleniya v reabilitatsii patsientov s bolezn'yu Parkinsona [Using biofeedback for rehabilitation of patients with parkinson’s desease]. Byulleten' sibirskoi meditsiny, 13(4), 38-42. [in Russian].

Ehgoetz Martens, K. A., Silveira, C. R. A., Intzandt, B. N., & Almeida, Q. J. (2018). State anxiety predicts cognitive performance in patients with Parkinson’s disease. Neuropsychology, 32(8), 950-957.

Helfrich, R. F., & Knight, R. T. (2019). Cognitive neurophysiology: Event-related potentials. In K. H. Levin, & P. Chauvel (Eds.). Clinical Neurophysiology: Basis and Technical Aspects (Vol. 160, pp. 543-558). Elsevier.

Holden, S. K., Finseth, T., Sillau, S. H., & Berman, B. D. (2017). Progression of MDS-UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson’s Progression Markers Initiative Cohort. Movement Disorders Clinical Practice, 5(1), 47-53.

Kaminska, M., Mery, V. P., Lafontaine, A.-L., Robinson, A., Benedetti, A., Gros, P., & Kimoff, R. J. (2018). Change in Cognition and Other Non-Motor Symptoms With Obstructive Sleep Apnea Treatment in Parkinson Disease. Journal of Clinical Sleep Medicine, 14(5), 819-828.

Lopes, M. da S., Melo, A. de S., & Nóbrega, A. C. (2014). Delayed latencies of auditory evoked potential P300 are associated with the severity of Parkinson’s disease in older patients. Arquivos de Neuro-Psiquiatria, 72(4), 296-300.

Martínez-Martín, P., Rodríguez-Blázquez, C., Forjaz, M. J., Álvarez-Sánchez, M., Arakaki, T., Bergareche-Yarza, A., Chade, A., Garretto, N., Gershanik, O., Kurtis, M. M., Martínez-Castrillo, J. C., Mendoza-Rodríguez, A., Moore, H. P., Rodríguez-Violante, M., Singer, C., Tilley, B. C., Huang, J., Stebbins, G. T., & Goetz, C. G. (2014). Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson’s disease patients. European Journal of Neurology, 21(3), 519-524.

Menon, B., Nayar, R., Kumar, S., Cherkil, S., Venkatachalam, A., Surendran, K., & Deepak, K. (2015). Parkinson′s disease, depression, and quality-of-life. Indian Journal of Psychological Medicine, 37(2), 144-148.

Özmüş, G., Yerlikaya, D., Gökçeoğlu, A., Emek Savaş, D. D., Çakmur, R., Dönmez Çolakoğlu, B., & Yener, G. G. (2017). Demonstration of Early Cognitive Impairment in Parkinson’s Disease with Visual P300 Responses. Noro Psikiyatri Arsivi, 54(1), 21-27.

Park, H. R., Youn, J., Cho, J. W., Oh, E.-S., Kim, J. S., Park, S., Jang, W., & Park, J. S. (2018). Characteristic Motor and Nonmotor Symptoms Related to Quality of Life in Drug-Naïve Patients with Late-Onset Parkinson Disease. Neurodegenerative Diseases, 18(1), 19-25.

Poskotinova, L. V., Krivonogova, E. V., Khasanova, N. M., & Krasnikova, M. N. (2016). Vozmozhnost' prognoza motornykh i kognitivnykh narusheniĭ po dannym mezhpolusharnoĭ asimmetrii kognitivnogo vyzvannogo potentsiala R300 i simptomokompleksa pri bolezni Parkinsona [The Predictability of Motor and Cognitive Impairment According to Brain Asymmetry of Cognitive Evoked Potentials P300 and Features of Symptom Complex in Patients with Parkinson’s Disease]. Vestnik Rossiiskoi akademii meditsinskikh nauk, 71(1), 41-45. [in Russian].

Ruzimurodov, N., & Umarov, A. (2018). Features of P300 cognitive potentials in Parkinson’s disease. Parkinsonism & Related Disorders, 46(Suppl. 2), Article e80.

Skorvanek, M., Martinez-Martin, P., Kovacs, N., Rodriguez-Violante, M., Corvol, J.-C., Taba, P., Seppi, K., Levin, O., Schrag, A., Foltynie, T., Alvarez-Sanchez, M., Arakaki, T., Aschermann, Z., Aviles-Olmos, I., Benchetrit, E., Benoit, C., Bergareche-Yarza, A., Cervantes-Arriaga, A., Chade, A., … Stebbins, G. T. (2017). Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration. Movement Disorders Clinical Practice, 4(4), 536-544.

Titova, N., & Chaudhuri, K. R. (2017). Personalized medicine in Parkinson’s disease: Time to be precise. Movement Disorders, 32(8), 1147-1154.

Tokic, K., Titlic, M., Beganovic-Petrovic, A., Suljic, E., Romac, R., & Silic, S. (2016). P300 Wave Changes in Patients with Parkinson’s Disease. Medical Archives, 70(6), 453-456.

Veryugina, N. I., Glozman, G. M., & Vasenina, E. E. (2015). Metod kognitivnykh vyzvannykh potentsialov pri bolezni Parkinsona [Event-related potentials in Parkinson’s disease]. Zhurnal nevrologii i psikhiatrii im. C. C. Korsakova, 115(6-2), 50-53. [in Russian].

Zafar, S., & Yaddanapudi, S. S. (2020). Parkinson Disease. StatPearls Publishing.

How to Cite

Demchenko AV, Biriuk VV. Psychoemotional and cognitive characteristics in patients at the early stages of Parkinson’s disease. Zaporozhye Medical Journal [Internet]. 2020Apr.13 [cited 2024Jul.17];22(2). Available from:



Original research